The impact of new systemic treatments for psoriasis and psoriatic arthritis on perceptions of psoriasis and its treatment is not fully understood. |
The Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) survey aimed to understand how patient perceptions of treatment-related outcomes have evolved since the 2012 Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) survey, particularly for patients with mild to moderate psoriasis and/or psoriatic arthritis. |
The UPLIFT survey found persistent unmet needs and differences in perceptions of disease severity and treatment satisfaction between patients and physicians. |
There are opportunities to include special area involvement in assessments of disease severity, to enhance relationships between patients and dermatologists, and to improve outcomes in patients with psoriasis across the disease severity continuum. |
Introduction
Methods
Survey Design
Eligibility Criteria
Assessments
Analyses
Results
Prevalence of PsO and PsA
Patients who responded,a n | Patients screened on diagnosis,b n | Estimated population prevalence of PsO and/or PsA in screened patients, % | Estimated population prevalence of PsO in screened patients, % | Final sample,c n | Patients with PsO only in final sample, n (%) | Patients with PsO and PsA in final sample, n (%) | Patients with PsA only in final sample, n (%) | |
---|---|---|---|---|---|---|---|---|
Total | 264,054 | 227,637 | 6.65 | 4.06 | 3806 | 2550 (67.00) | 1064 (27.96) | 192 (5.04) |
USAd | 86,462 | 68,068 | 7.37 | 3.74 | 1006 | 535 (53.18) | 399 (39.66) | 72 (7.16) |
Canada | 16,137 | 14,976 | 6.53 | 4.32 | 403 | 282 (69.98) | 70 (17.37) | 51 (12.66) |
UK | 19,118 | 17,198 | 6.38 | 4.42 | 400 | 307 (76.75) | 80 (20.00) | 13 (3.25) |
Germany | 20,490 | 18,484 | 7.07 | 3.44 | 403 | 229 (56.82) | 156 (38.71) | 18 (4.47) |
France | 12,315 | 11,409 | 9.32 | 6.25 | 404 | 310 (76.73) | 78 (19.31) | 16 (3.96) |
Italy | 24,073 | 20,925 | 11.26 | 8.00 | 401 | 295 (73.57) | 100 (24.94) | 6 (1.50) |
Spain | 26,962 | 24,251 | 8.58 | 5.61 | 398 | 299 (75.13) | 90 (22.61) | 9 (2.26) |
Japan | 58,497 | 52,326 | 2.37 | 1.73 | 391 | 293 (74.94) | 91 (23.27) | 7 (1.79) |
Patient Demographics and Dermatologist Practice Characteristics
Characteristic | N = 3806 |
---|---|
Age, mean, years | 45.1 |
Sex, n (%) | |
Male | 1914 (50.3) |
Female | 1892 (49.7) |
BMI category (kg/m2), n (%) | |
Underweight (< 18.5) | 103 (3.4) |
Normal (18.5–24.9) | 1429 (47.4) |
Overweight (25.0–29.9) | 882 (29.2) |
Obese (≥ 30) | 603 (20.0) |
Comorbidities, n (%) | |
Arthritisa | 1157 (30.4) |
Cancer | 693 (18.2) |
Depression | 1257 (33.0) |
Diabetes | 903 (23.7) |
Heart disease | 520 (13.7) |
Hypertension | 1342 (35.3) |
Inflammatory bowel diseaseb | 512 (13.5) |
Liver disease | 419 (11.0) |
PsO in special areasc | n = 3606 |
Scalp | 1930 (53.5) |
Face | 1016 (28.2) |
Palms | 620 (17.2) |
Nails | 602 (16.7) |
Soles | 476 (13.2) |
Genitals | 442 (12.3) |
PsO symptomsd | n = 3614 |
Itching | 3362 (93.0) |
Redness | 3361 (93.0) |
Flaking | 3267 (90.4) |
Scales | 3244 (89.8) |
Burning/stinging | 2858 (79.1) |
Pain | 2659 (73.6) |
Bleeding | 2550 (70.6) |
Nail separation, crumbling, discoloration, etc. | 602 (16.7) |